MannKind Corporation (MNKD) Stock Analysis & Winston Score

MannKind Corporation is a biotechnology company that makes medicines for people with diabetes and a rare lung disease. Its main product is Afrezza, an inhaled insulin that diabetic patients breathe in through their lungs instead of injecting with a needle. MannKind also sells Tyvaso DPI, an inhaled treatment for pulmonary arterial hypertension, which it commercializes in partnership with United Therapeutics. MannKind earns money through product sales of Afrezza and through royalties and manufacturing revenue tied to its Tyvaso DPI partnership. The company operates primarily in the United States and is relatively small, with a market cap around $1.3 billion. Its proprietary Technosphere drug delivery platform — which turns medicines into a powder that can be inhaled — is a key differentiator, but Afrezza has struggled to gain wide adoption against entrenched injectable insulin brands. The biggest growth question is whether MannKind can meaningfully expand Afrezza's market share while its partnership revenue remains a financial lifeline.